Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194124 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
A Phase 3 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT05194124 is a Phase 3 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT05194124, a Phase 3 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
Interventions
- DRUG Setmelanotide 2 mg
- DRUG Setmelanotide 2.5 mg
- DRUG Setmelanotide 3 mg
- DRUG Setmelanotide 20 mg
- DRUG Setmelanotide 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05194124
The ClinicalTrials.gov registry entry for NCT05194124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Setmelanotide 2 mg is the first listed.
NCT05194124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05194124 about?
NCT05194124 is a clinical study titled "Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway". A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
What is the current status of trial NCT05194124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2021-12-21. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT05194124?
The interventions under investigation include: Setmelanotide 2 mg (DRUG), Setmelanotide 2.5 mg (DRUG), Setmelanotide 3 mg (DRUG), Setmelanotide 20 mg (DRUG), Setmelanotide 25 mg (DRUG).
Who is sponsoring clinical trial NCT05194124?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.